BHMP
RVNC

Bardin Hill Management Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bardin Hill Management Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-684
Closed -$23K – 121
2014
Q2 		$23K Buy
+684
New +$21.4K ﹤0.01% 100

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Bardin Hill Management Partners's RVNC Position: Q3 2014 in Review

Bardin Hill Management Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2014, closing a stake of 684 shares — an estimated $23K sold.

Bardin Hill Management Partners first reported a position in RVNC in Q2 2014 and held it in 1 quarter. The position peaked at $23K in Q2 2014. 80 funds tracked by Wall St. Rank hold RVNC as of Q3 2014.

  • Bardin Hill Management Partners reported no remaining Revance Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Bardin Hill Management Partners sold 684 Revance Therapeutics, Inc. shares in Q3 2014, an estimated $23K.
  • Bardin Hill Management Partners first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • Bardin Hill Management Partners's Revance Therapeutics, Inc. position peaked at $23K in Q2 2014.
  • 80 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2014.

Based on Bardin Hill Management Partners's 13F filing for Q3 2014, filed 14 Nov 2014.